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Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-
versus-myeloma eﬀect. This role of immune eﬀector cells provides the framework for the development of immune-based ther-
apeutic options that use antigen-presenting cells (APCs) with increased potency, such as dendritic cells (DCs), in MM. Current
isolated idiotype (Id), myeloma cell lysates, myeloma dying cells, DC-myeloma hybrids, or DC transfected with tumor-derived
RNA has been used for immunotherapy with DCs. Immunological inhibitory cytokines, such as TGF-β, IL-10, IL-6 and VEGF,
whichareproducedfrommyelomacells,canmodulateantitumorhostimmuneresponse,includingtheabrogationofDCfunction,
by constitutive activation of STAT3. Therefore, even the immune responses have been observed in clinical trials, the clinical
response was rarely improved following DC vaccinations in MM patients. We are going to discuss how to improve the eﬃcacy
of DC vaccination in MM.
1.Introduction
Multiple myeloma (MM) is a clonal B cell malignant disease
that is characterized by the proliferation of plasma cells
in the bone marrow (BM) in association with monoclonal
protein in the serum and/or urine, immune paresis, skeletal
destruction, renal dysfunction, anemia, hypercalcemia and
lytic bone diseases [1, 2]. Although the introduction of con-
ventionalchemotherapy,high-dosetherapywithhematopoi-
etic stem cell transplantation (HSCT), and the development
of novel molecular target agents has resulted in a marked im-
provement in overall survival, the disease still remains in-
curable [3, 4]. Alternative approaches are clearly needed to
prolong the disease-free survival, as well as the overall sur-
vivalofpatientswithMM.Toprolongthesurvivalofpatients
with MM who are undergoing allogeneic HSCT, donor lym-
phocyte infusion can be used successfully as a salvage ther-
apy, which is based on the graft-versus-myeloma eﬀect in
some cases of MM that relapse after allogeneic HSCT [5–7].
Thisroleofimmuneeﬀectorcellsprovidestheframeworkfor
the development of immune-based therapeutic options that
use antigen-presenting cells (APCs) with increased potency,
such as dendritic cells (DCs), in MM [6, 7].
DCs are the most potent APCs for initiating cellular
immune responses through the stimulation of naive T cells.
Immature DCs are good at antigen uptake and processing,
but for a stimulatory T-cell response they must mature to
become fully activated DCs, which express high levels of cell
surface-related major histocompatibility complex- (MHC-)
antigen and costimulatory molecules. Because of their ability
to stimulate T cells, DCs act as a link in antitumor immune
responses between innate immunity and adaptive immunity
[8]. These DCs play a central role in various immunotherapy
protocols by generation of cytotoxic T lymphocytes (CTLs)
[9]. DC-based vaccines have become the most attractive
tool for cancer immunotherapy and have been used in2 Clinical and Developmental Immunology
thetreatmentofmorethan20malignancies,mostcommonly
melanoma, renal cell carcinoma, prostate cancer, and col-
orectal carcinoma [10, 11]. In MM, cellular immunotherapy
usingDCsisemergingasausefulimmunotherapeuticmoda-
lity to treat MM [10]. Since tumor antigen-loaded DCs are
expected to be able to stimulate tumor-speciﬁc CTLs and
to overcome T cell tolerance in tumor patients, the devel-
opment of DC vaccines that can consistently eliminate mini-
mal residual neoplastic disease remains an important goal in
the ﬁeld of tumor immunology [12].
2. Current DC Therapy in MM
MM is believed to induce immunoparesis that interferes
with DC function, which diminishes the eﬀective antitumor
immune responses in these patients. Usually, ex vivo DCs
are generated from circulating blood precursors (i.e., mono-
cytes) or bone marrow progenitor cells and are educated
with tumor antigens prior to vaccination to patients. Ex vivo
generated DCs can be loaded with myeloma-associated anti-
gens as vaccines for patients with MM. The use of immature
DCsormatureDCs,thewaytoinduceDCmaturation,types
of tumor antigens, the techniques to load tumor antigens
to DCs, routes of administration, and dosing schedules are
being investigated [13].
2.1. Idiotype-Pulsed DCs. Immunoglobulin Idiotype (Id) is
a tumor-speciﬁc antigen can be deﬁned that each B cell
tumor clone produces. Id can be readily isolated from the
plasma of MM patients [14]. The Id protein has been used
for immunotherapy both in vitro and in vivo in MM and has
demonstrated a successful response in follicular lymphoma
and a unique expression of Id on the malignant B cell clone
[15, 16]. Id vaccination could induce both antibody and
Id-speciﬁc T cells including CD4+ T cell and CD8+ Tc e l l
response by the presentation of Id protein on MHC class I
and II of professional APCs, such as DCs. Id-speciﬁc CTL
lines could be generated that killed autologous primary my-
eloma cells in vitro, and killing activity was induced by only
MHC class I restricted [17], while in the other report both
c l a s sIa n dc l a s sI Ir e s t r i c t i o nw a so b s e r v e d[ 18]. Autologous
DCsthatweregeneratedfromMMpatientshavebeenshown
to eﬃciently endocytose diﬀerent classes of Id protein, and
autologous Id-speciﬁc CTLs lines containing both CD4+ and
CD8+ T cells that were generated by Id-pulsed DCs sig-
niﬁcantly recognized and killed the autologous primary my-
eloma cells in vitro [18, 19]. Until now, the various studies
of DC-based Id vaccination in MM have been reported [20–
27]. Although Id-speciﬁc CTLs and immune response could
be induced in some patients, clinical responses have been
observed rarely in few patients after vaccination [22]. To
improve the eﬀectiveness of DC vaccination, the Id-pulsed
DCs were vaccinated in combination with KLH or cytokine
IL-2inMMpatients[21,23,26].However,evenbothcellular
and antibody responses have been observed, the clinical
response also was not improvement following vaccinations.
The reasons for these results may be attributed mainly to the
Id protein as a weak antigen, and the use of immature DCs in
some studies [20, 28, 29].
2.2. Myeloma-Associated Antigens-Loaded DC. Tumor-asso-
ciated antigens (TAAs) have been identiﬁed in many tumor
types including solid tumors and hematological malignan-
cies. The highly speciﬁc TAAs overexpress in increasing
amounts in malignant cells were the greatest potential for
clinicallyusefulassays.Avarietyofmyeloma-associatedanti-
gens have been identiﬁed in MM patients, which possibility
provides an immune response by DC-based vaccine. T cells
from myeloma patients can recognize a variety of TAAs,
which suggesting that the T cell has the capacity to kill
myeloma cells selectively if these clonal populations can be
activated and expanded eﬀectively by a potent TAA. Many
potential TAAs in MM have been investigated including
polymorphic epithelial mucin (MUC1), human telomerase
reverse transcriptase (hTERT), PRAME, HM1.24, SP17,
Wilms’ tumor I (WTI), Dickkopf-1 (DKK1), or member of
cancer germ-like family (MAGE, GAGE, BAGE, LAGE, NY-
ESO-1) [30–35]. Among the various TAAs, some have been
tested as peptide vaccines and only a few of them has been
testedinvitrotoinduceTAA-speciﬁcCTLsresponseviaload-
ing the potent TAA to DCs in MM. The ﬁrst TAAs pulsed
with DCs in MM was MUC1, which was expressed on all
of MM cell lines and primary myeloma cells and in sera
of MM patients. Vaccination with MUC1 antigen has not
been studied in MM patients, but MUC1-speciﬁc CTLs that
were induced in vitro using peptide-pulsed DCs or plasma
cell RNA-loaded DCs eﬃciently killed not only target cells
pulsed with the antigenic peptide but also MM cells [31, 36].
NY-ESO-1 is the most immunogenic of the cancer testis
antigens, which are expressed in a variety of tumors, while
their presence in normal tissue is limited to the testis and
placenta [35]. In MM, expression of NY-ESO-1 has been cor-
related with more advanced disease [37]. Spontaneous hu-
moral and CD8+ T cell-mediated responses to NY-ESO-
1 have been identiﬁed in patients with advanced disease
[35,37].Theinvitromonocyte-derivedDCstransducedwith
the PTD-NY-ESO-1 protein can induce CD8+ cellular anti-
tumor immunity superior to that achieved with NY-ESO-1
protein alone [30]. Sperm protein 17 (Sp17), the other im-
munogenic TAA, has been used as a tumor antigen to load
intoDCs.Sp17-speciﬁcHLAclassIrestrictedCTLsweresuc-
cessfully generated by DCs that have been loaded with a
recombinant Sp17 protein and the CTLs were able to kill
autologous tumor cells that expressed Sp17 [38, 39]. The
over-expression of hTERT on MM compared to normal cells
indicatedthatthistelomerasecouldbeusedastumorantigen
to induce antitumor immune responses. hTERT was capable
of triggering antitumor CTL responses and kill hTERT+
tumor cells [40]. Recently, the CTLs that were stimulated by
hTERT- and MUC1-derived nonapeptides loaded DCs were
successfullyabletokillmyelomacellline[41].DKK1,anovel
protein that is not expressed in most normal tissues but is
expressed in almost myeloma cells, could be a potentially
importantantigenictargetforantimyelomaimmunotherapy.
DKK1-speciﬁc CTLs that were generated by DCs pulsed with
DKK1 peptides were speciﬁcally lysed autologous primary
myeloma cells and DKK1-positive cell line [34]. In general,
TAAs could be a major interest in immunotherapy in MM.
Taken together, the data support DC immunotherapy withClinical and Developmental Immunology 3
TAAs as being a promising immunotherapy to support to
clinical trials in MM.
3. Whole Tumor Antigen-LoadedDC
An alternative to Id protein- or TAA-based immunotherapy
in MM is to use other tumor antigens that derived from
whole tumor preparation to improve the eﬃcacy of the DC
vaccination in patients with MM. DCs loaded with antigens
derived from whole tumor cells can improve the antitumor
response and that limits the risk for immunological escape.
There have been increasing reports of these alternative ap-
proaches, such as DCs pulsed with myeloma lysates [42–44],
DCspulsedwithmyelomaapoptoticbodies[43,45,46],DCs
transfected with myeloma-derived RNA [36], DCs pulsed
with myeloma-derived heat shock protein (HSP) gp96
[47, 48], or DC-myeloma cell hybrids [49–51]. These techni-
ques have the advantage of allowing the presentation of
multiple epitopes to MHC on DCs, therefore can induce
polyclonal T-cell response from many potentially unknown
TAAs and reduce the probability of immune escape by single
TAA. DCs loaded with myeloma cell lysates demonstrated
much stronger cytotoxicity against autologous plasma cells
than did those by Id protein-pulsed DCs, which suggested
the superiority of the myeloma cell itself as a source of a tu-
mor antigen compared with the Id protein [44]. In other
myeloma model, DCs pulsed with puriﬁed and optimized
myeloma cell lysate were shown to generate CTLs that killed
autologous tumor cells but not against mismatch HLA cell
lines or K562 cell lines in vitro [43]. The apoptotic bodies
derived from either myeloma cell lines or patient’s myeloma
cells also have been used as tumor antigen to loading with
DCs. Interestingly, apoptotic bodies were shown to be more
eﬀective than cell lysate at inducing CTLs against autologous
myeloma cells [42]. Heat shock proteins (HSPs) are a class of
functionally related proteins whose expression is increased
when cells are exposed to elevated temperatures or other
stress. Tumor-derived HSPs, such as HSP70 and gp96, are
immunogenic and potent in stimulating the generation of
tumor-speciﬁc CTLs. The myeloma-derived gp96 loaded
DCs were used to generate tumor-speciﬁc CTLs that were
able to lyse myeloma tumor cells but not normal blood cells
inaMHCclassIrestrictedmanner[47,48].Inotherway,the
fusions of autologous DCs with patient-derived tumor cells
have been developed. Fusion cells can stimulate both helper
and cytotoxic T-cell responses through the presentation of
internalized and newly synthesized antigens [51]. In mouse
MMmodels,vaccinationwithDCsfusedwitheitherplasma-
c y t o m ac e l l so rt u m o rc e l l st h a tw e r eg e n e t i c a l l ym o d i ﬁ e dt o
express CD40L resulted in eradication of disease in tumor-
bearing animal and protective against subsequent tumor
challenge in animals [49, 50]. In general, the production of
DC vaccine by using whole tumor antigens has become pro-
mising in order to induce immunotherapy against MM.
4.DC-BasedVaccineClinicalTrials
Clinical trials of DC-based vaccine for MM have been re-
stricted until now. The trial protocol and responses are
summarized in Table 1. ALmost of the clinical trials were
related with using Id-pulsed DC alone or in combination
with adjuvant such as cytokines or KLH. In the decade after
the ﬁrst DC-based Id vaccination was started at Stanford
University, the results of clinical trials were limited. In gen-
eral, the majority of clinical trials conducted using Id-
pulsedDCsshowedimmuneresponses.However,theclinical
responseswereunsatisfactory,mainlyduetothepoorimmu-
nogenicity of the Id protein. More recent results demon-
strated improved clinical response by DC-based Id vaccina-
tion [26, 27]. Therefore, DC-based Id vaccination is going
to a possible way to induce the speciﬁc T cell responses in
myeloma patients. Further trials with increasing numbers of
patients are needed to increase the rate of responses.
Most recently, phase I study was undertaken, in which
patients with MM were vaccinated with an autologous DC/
tumor cell fusion in combination with GM-CSF administra-
tion on the day of DC vaccination [52]. Vaccine generation
was successful in 17 of the 18 patients. The expansion of
circulating CD4+ and CD8+ T cells reactive with autologous
myeloma cells in 11 of 15 evaluable patients were detected. A
majorityofpatients(11of16)withadvanceddiseasedemon-
strated disease stabilization, with three patients showing
ongoingstablediseaseat12,25,and41months.Interestingly,
antibody response against some TAAs, such as regulators of
G-protein signaling 19 (RGS19), HSP90, BRCA1-associated
protein (BRAP), was also detected. So, vaccination with
DC/MM fusions was feasible and may provide a new source
of DC-based vaccines for the development of immunother-
apy against MM.
A commercial product is currently being tested in phase
IIItrial(Mylovenge,DendreonCorp,Seattle,WA,USA).My-
lovenge (APC8020) is conducted by pulsing autologous DCs
with the patient’s Id. A recent report of this commercial
product showed that the long-term survival of those receiv-
ing the vaccine compared to all other patients with MM
whounderwentautologousHSCT[53].Thisapproachneeds
further testing in phase III trial to conﬁrm the clinical re-
sponse and deﬁne the role of this DC vaccine in MM. We
arealsoconductingphaseI/IIclinicaltrialusingtype-1-pola-
rized DCs loading with tumor antigens derived either from
allogeneic myeloma cell line or patient’s autologous-/allo-
geneic-myeloma cells in combination with chemotherapy in
patients with MM after autologous HSCT.
5. How to ImproveDC VaccinationinMM?
During recent decades, cancer immunotherapy using DC-
based vaccines has been used as therapeutic in patients with
cancer including MM patients, however, while a few number
of patients can really induce tumor regressions, one of the
most common responses of the current DC vaccination is
only a demonstration of antigen-speciﬁc immune responses,
but no evidence of tumor regression. This unexpectation
provides the new strategy for the treatment of cancer in
which the intrinsic abilities of the immune system response
to the DC vaccine has been modiﬁed to enhance the eﬃcacy
of vaccination. Several studies indicate that the immune4 Clinical and Developmental Immunology
Table 1: Summary of clinical trials of DC-based vaccine for MM.
Author DC type TA Adjuvant Immune responses Clinical responses
Liso et al. imDC Id ±KLH 4/24 Id-speciﬁc 17/26 SD
Lim et al. imMo-DC Id KLH
5/6 Id-speciﬁc; 2/6 Id-speciﬁc
IFN-γ; 3/6 increase in
Id-speciﬁc CTL frequency
6/6 PD
Reichardt
et al. imDC Id none 2/12 Id-speciﬁc proliferation;
1/3 Id-speciﬁc CTL
2 relapse; 8/10 PD; 2/10
SD
Titzer et al. CD34-DC Id none
4/10 Id-speciﬁc T cell
proliferation; 1/10 decreased
BM plasmacytosis
1/10 SD; 9/10 PD
Cull et al. imMo-DC Id none
2/2 Id-speciﬁc T cell
proliferation; no Id-speciﬁc
CTL response
2/2 PD
Yi et al. mMo-DC Id Il-2
2/5 Id-speciﬁc T cell
proliferation; 5/5 Id-speciﬁc B
cell proliferation; 4/5
Id-speciﬁc IFN-γ
1/3 PR; 3/5 SD; 1/5 PD
Bendandi
et al. mMo-DC Id none 4/4 anti-KLH response; 2/4
Th1 cytokines response 1/4 SD; 3/4 PD
Lacy et al. APC8020
(Mylovenge) Id none None reported
6/26 CR; 2/26 PR; 19/27
SD overall survival: 5.3
years of followup for
alive patients
Lacy et al. CD40 L-DCs Id KLH
9/9 Id-speciﬁc IFN-γ;5 / 9
Id-speciﬁc CTL response; 8/9
anti-KLH response
6/9 SD; 3/9 slowly PD
4/6 continue SD after 5
years
Rosenblatt
et al.
DC/tumor
fusion GM-CSF
11/15 CD4 and CD8 response
with autologous myeloma
cells; 5/5 tested anti-MUC1
response
11/16 SD (3/11 > 1 years
SD; 8/11 2.5–5 months
SD)
Rollig et al. mMo-DC Id KLH
5/9 Id-speciﬁc T cell
proliferation; 8/9 Id-speciﬁc
cytokines response
3/9M protein decrease;
5/9M protein stable
DC: dendritic cell; TA: tumor antigen; imDC: immature DC; Mo-DC: monocyte-derived DC; Id: idiotype; mMo-DC: mature Mo-DC; KLH: keyhole limpet
hemocyanin; CTL: cytotoxic T lymphocyte; PD: progressive disease; PR: partial response; SD: stable disease; CR: complete response.
system of cancer patients can recognize and kill tumors;
however, some cancer patient cannot induce the immune
response against tumor. In particularly, ex vivo DCs are
usually generated from cancer patients, however, patients
with cancer including MM have basically dysfunctional DCs
[54–57]. DC function is mainly aﬀected by the microenviro-
nment in which they can stimulate immune response [58].
The present of several immunosuppressive factors in tumor
microenvironment including the high production of in-
hibitory cytokines (interleukin-(IL-) 10, transforming
growth factor beta (TGF-β), vascular endothelial growth fac-
tor (VEGF), and IL-6), the activation of STAT3, the expan-
sion of Treg cells, and the signiﬁcant suppressive eﬀect of
MDSC has been investigated [55–57, 59–64]. Therefore, the
recent new idea now is how to improve the eﬃcacy of DC
vaccinetoincreasetheeﬀectivenessofvaccinationagainsttu-
mors.
For improving clinical outcomes using DC-based immu-
notherapy, there have been increasing reports of alternative
approaches,suchasbettercytokinecombinationstoenhance
DC function, eﬀective tumor antigens to induce speciﬁc
CTLs, or modifying signal transcriptions to overcome defec-
tive DC function. Our experience in the DC research ﬁeld
has revealed several key points to improve DC vaccination in
cancer patients including MM (Figure 1).
5.1. Enhancing the Maturation and Activation of DCs by
Th1 Polarizing Cytokines. For eﬀective induction of tumor-
speciﬁc immune responses in the ﬁeld of DC vaccination,
the DCs should have potency to stimulate T cells, to pro-
duce high levels of Th1-polarized cytokines (IL-12p70), to
trigger Th1 polarizing capacity, and to migrate through
lymphatic vessels to interact with T cells. The initial success
of the therapeutic vaccines involving immature or partially-
mature “ﬁrst-generation” DCs has been reported [65]. How-
ever, such DCs express suboptimal levels of costimulatory
molecules, and constitute a weaker immunogen than the
subsequently implemented mature DCs, constituting the
“second generation” of clinically applied DCs (sDCs). sDC
vaccines induced by the IL-1β/TNF-α/IL-6/prostaglandinClinical and Developmental Immunology 5
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Potent↑
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Potent↑
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Suppressive environment↓
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nodes
Vaccination
Figure 1: Key points to improve DC vaccination in cancer patients. CTL: cytotoxic T lymphocyte; DCs: dendritic cells; TA: tumor antigen;
LNs: lymph nodes; Treg: regulatory T cell; MDSC: myeloid-derived suppressor cell.
E2 (PGE2) cytokine cocktail have been developed [66]. Such
DCs are fully mature DCs with high expression of costimul-
atory molecules, high expression of CCR7, and high migra-
tory responsiveness to LN-associated chemokines; they have
beenwidelytestedinclinicaltrials.However,todate,thesDC
vaccines have limitations that include the mediation of Th2
polarization, promotion of DC secretion of the immuno-
suppressive cytokine IL-10, inability to induce eﬀectively the
Th1-type response (because PGE2 abolishes the secretion of
IL-12p70), and high activity of such DCs in activating Treg
cells [67–70].
Several investigators, including our group, have tried to
develop the potent DCs for inducing eﬀective tumor-speci-
ﬁc immune responses. In an attempt to increase DC poten-
cy using cytokine combinations, α-type-1-polarized DCs
(αDC1s) that are induced to mature using the αDC1-induc-
ingcytokinecocktailIL-1β,TNF -α,IFN-α,IFN-γ,andpolyi-
nosinic: polycytidylic acid [poly(I:C)] has been developed to
generate strong functional CTLs in several diseases, on aver-
age 20-fold higher compared to sDCs [71, 72]. Recently, we
successfully generated αDC1s from a patient with MM with
high expression of costimulatory molecules, signiﬁcant pro-
duction of IL-12p70, and potent generation of myeloma-
speciﬁcCTLs[43,46].Suchanovelappropriatestrategypro-
vides a way to improve the potency of ex vivo generated DCs
for cancer therapy.
5.2. Enhance the Maturation and Activation of DCs by Natural
Product as TLR Signaling. Ursolic acid (URC) is isolated
from Uncaria rhynchophylla and phytochemically classiﬁed
astriterpene.Triterpenecompoundshavebeenidentiﬁedasa
uniqueclassofnaturalproductspossessing diversebiological
activities. Recently, we have reported that URC activates
human DCs in a fashion that favors Th1 polarization via the
activation of IL-12p70 dependent on TLR2 and/or TLR4 and
induces the production of IFN-γ by CD4+ na¨ ıve T cells [73].
In addition, the combination of URC and IFN-γ enhance
the activation of DCs, namely, the enhancement of Th1 cells
polarizationthatinducedbyIFN-γ dependsontheactivation
of IL-12p70 and independent on TLR4 [74]. The potential of
natural product to enhance DC maturation and activation
has important implications for the use of DCs as cancer
vaccines.
5.3.EnhancetheCross-PresentationofDCsbyTumorAssociat-
ed Antigens. As described above, the results of immunother-
apy with Id-pulsed DCs have been unsatisfying. The use of
TAA can induce the higher immune response compared to
Id. Although a single TAA has the possibility to induce the
antitumor immune responses against MM, tumors may es-
cape immune recognition by downregulating expression of a
particular antigen. However, TAA can induce autoimmunity.
Several TAAs have been detected in normal tissues. In6 Clinical and Developmental Immunology
addition, only a small number of tumor samples from MM
patientsshowedasimilarlevelofTAAexpressing,limiting its
usefulness for using TAA in MM. Therefore, to overcome the
eﬀect of TAAs-based immunotherapy, our group tries to use
other tumor antigens that improve the cross-presentation of
the DC vaccination in patients with MM.
The selected antigen should possess the best characteris-
tics to induce high cross-presentation, be tumor speciﬁc, be
e a s i l ya v a i l a b l e ,a n db eu n a b l et oi n d u c ei m m u n es u p p r e s -
sion. Whole tumor antigens is the best tumor antigen, which
has been selected by many investigator including myeloma
cell lysates [42–44], apoptotic bodies from myeloma cell line
[43, 45, 46]. In practical terms, there are a number of pa-
tients with MM, who have less than 50% of myeloma cells
in the bone marrow at the time of diagnosis or during pro-
gression of the disease. When mononuclear cells from the
bone marrow are used as a source of tumor antigens, there
is the potential of contamination with normal cells, espe-
cially lymphocytes. Thus, it is necessary to use puriﬁed and
optimized myeloma cells, if possible, as a source of tu-
mor antigen for the generation of myeloma-speciﬁc CTLs
stimulated by DCs [43]. We have shown that the function
of the DCs was aﬀected by the concentration of myeloma
cell lysates (i.e., higher concentrations of lysates suppress T
cell stimulatory capacities more than lower concentration of
lysates). Also, the optimization of the lysate concentration
did not demonstrate any inferiority in functions, such as
T cell stimulatory capacities and cytotoxicities, of the DCs
compared with other antigens, such as apoptotic bodies of
myeloma cells or formalin-ﬁxed myeloma cells. CTLs that
were generated by puriﬁed and optimized myeloma cell
lysates pulsed with DCs demonstrated much stronger cyto-
toxicity against autologous plasma cells. These ﬁndings indi-
catethatit is important to optimize the concentrationofmy-
eloma cell lysates that were loaded onto DCs to potentiate
their function.
The use of whole tumor cells, instead of single antigens,
may help to enhance antitumor eﬀe c t sb u tt a r g e tm u l t i p l e
tumor variants and counteract tumor immune evasion.
However, it is impractical to obtain suﬃcient amounts of
puriﬁed autologous myeloma cells for tumor antigens in the
clinical setting of patients with MM. As an alternative source
of tumor-relevant antigens, allogeneic tumor cells or est-
ablished cancer cell lines have been used to overcome this
limitation in various tumors [43, 46, 75, 76]. Allogeneic my-
eloma cell lines used as universal tumor antigens could
substitute for an original tumor cell collection and make the
culture of tumor cells easier. In clinical practice, allogeneic
myeloma cell lines might be an eﬀective source of universal
tumor antigen that could be used to load DCs for the gen-
eration of myeloma-speciﬁc CTLs in MM patients. Tumor
antigensthatderivedfromirradiatedallogeneicmyelomacell
line when loaded with DCs could generate myeloma-speciﬁc
CTLs against autologous myeloma cells in patients with MM
[45, 46]. The success of using an allogeneic myeloma cell
line as tumor antigen led to the possibility that allogeneic
myeloma cells could be also used as a viable source of tumor
antigen in the context of appropriate major MHC alleles
to autologous CTLs. We investigated the possibility of DC
therapy using autologous DC loaded with apoptotic allo-
geneic myeloma cells from the matched monoclonal subtype
of myeloma patients and showed that the CTL generated by
these tumor antigens loaded DCs could generate myeloma-
speciﬁc CTLs against autologous myeloma cells in patients
with MM [77]. These ﬁndings suggested that allogeneic
myeloma cell lines and the allogeneic matching monoclonal
immunoglobulin subtype of myeloma is the eﬀective tumor
antigencapableofinducingfunctionalCTLsagainstpatients’
own tumor cells.
5.4. Blocking the Immunosuppressive Activity. The suppres-
sive eﬀects of tumor cells during DC generation have been
explained previously by the ability of the tumor microenvi-
ronmenttosuppressDCdiﬀerentiation[60,78].Inaddition,
patients with MM have DCs that are functionally defective,
evidenced by the decreased number of circulating precursors
o fD C sa sw e l la si m p a i r e dT - c e l ls t i m u l a t o r yc a p a c i t y[ 55–
57]. DCs in MM patients are a target of tumor-associated
suppressive factors, such as IL-10, TGF-β,V E G F ,a n dI L -
6, resulting in their aberrant functions and impaired devel-
opment of eﬀector functions in tumor-speciﬁc lymphocytes
[55, 56]. These factors can inﬂuence the activation of STAT3
and extracellular signal-regulated kinase (ERK) phosphory-
lation,resultinginhyperactivationofSTAT3andERK,which
may be responsible for defective DC diﬀerentiation [60, 79].
In addition to generation of potent and speciﬁc tumor anti-
gen-loaded DCs for vaccination, alternative methods have
attempted to restore defective DC function and to enhance
DC function in MM. Enhanced immune-mediated antitu-
mor eﬀects of DCs have been reported following the inhi-
bition of the janus-activated kinase 2 (JAK2)/STAT3 pathway
[80–82], inhibition of p38 or activation of the MEK/ERK
or mitogen-activated protein kinase (MAPK) pathways, and
neutralization of IL-6 [83]. Recently, we reported that the
inhibitory factors and abnormal signaling pathways of DCs
during maturation with tumor antigen might be respon-
sible for the defective activity of DCs in MM and suggested
that the way to overcome these abnormalities is by neutraliz-
ing the signaling that would lead to a suppressed immune
response [84]. More recently, we are developing of the
strategies that recovering dysfunction of DCs caused from
loading tumor antigen through the treatment of a combi-
nation of the selective JAK/STAT3 signaling pathway inhibi-
tor (JSI-124) and the proteasome inhibitor (Bortezomib)
onto myeloma cells (unpublished data). We reported that
pretreatment of myeloma cells with combination of JSI-124
and bortezomib can recover DC dysfunction from loading
the dying myeloma cells through the upregulation of Hsp90
and the downregulation of STAT3 phosphorylation and in-
hibitory cytokines production, and these DCs can generate
to potent myeloma-speciﬁc CTLs.
5.5. Natural Killer (NK) Cells and Helper Functions during
Induction of Type 1 Immunity by DCs. The other strategy to
induce potent DCs from patients with MM was the use of
a “helper” cell to promote type 1 polarization of DCs. NK
cells are rapidly homing to the sites of infection and con-
trol the immune response in viral infections. Indeed, it hasClinical and Developmental Immunology 7
been demonstrated that NK cells play a major immuno-
regulatory role in the development of a protective T-cell-
mediated immunity against intracellular pathogens and can-
cer [85–87]. Such “helper” activity of NK cells is at least
partially mediated by the functional modulation of DCs, the
phenomenon depending on the production of IFN-γ and
TNF-αbyactivatedNKcells[85–87],andassociatedwithen-
hanced cross-presentation of tumor antigens and the induc-
tionofTh1andCTLresponses[45,88,89].Recentdatafrom
our and other groups demonstrate that such NK-DC inter-
action promotes the subsequent induction of tumor-speciﬁc
responses of CD4+ and CD8+ T cells, allowing NK cells to
act as “helper” cells in the development of the type 1 DCs in
responses against cancer [45, 88, 89]. Resting NK cells that
are activated in the presence of TLR agonist, IL-2, and IFN-α
can induce DCs from patients with MM maturation and en-
hance IL-12p70 production in vitro. These potent DCs can
be developed to generate strong functional CTLs against my-
eloma cells compared to sDCs [45].
5.6. Treg Cells and MDSC Regulation. Therapeutic DC vac-
cines against cancer not only need to be highly eﬀective in
inducing the expansion of tumor-speciﬁc T cells, but they
also need to avoid interaction and induction of Tregs. How-
ever, MM induces immune paresis [54]. Tumors are able
to escape immune surveillance by down-regulation of im-
mune responses as well as through the production of immu-
nosuppressive cytokines by the tumor cells or by activation
of suppressor cells such as regulatory T cells (Treg) and
myeloid-derived suppressor cells (MDSCs) [90]. Dysregula-
tion of natural CD4+CD25+ T regulatory (Treg) in MM has
been reported [91]. Tregs are a group of immunosuppressive
T cells that have been implicated in the suppression of tumor
immunity [92]. A higher number of Tregs were reported in
myeloma capable of suppressive activity at T-cell stimulation
[61]. Recently, the discovery of MDSCs revealed these cells as
potent suppressors of tumor immunity and, therefore, a sig-
niﬁcantimpedimenttocancerimmunotherapy[63].MDSCs
can suppress the activation of T cells, B cells, NK cells and
NKT cells. In contrast, MDSCs can enhance the induction
of Tregs [64]. Recently, a human study reported that the
proportion of CD4+FoxP3+ Treg cells and CD14+HLA-
DR−/low MDSC was increased in patients with MM at di-
agnosis was described [62]. These cells were functionally
intact as they were able to inhibit proliferation of both CD4
and CD8 T cells illustrating that this cell fraction is also
distorted in patients with MM [62].
The type-1-polarized DCs were demonstrated to sup-
press the secretion of CCL22 (Treg and Th2 type attracting
chemokines), enhance the secretion of CCL5 and CXCL10
(Th1 and eﬀector T-cell-attracting chemokines), and sup-
press the induction of Tregs compared to sDCs or PGE2-
matured DCs [93]. In addition, to enhance the antitumor ef-
fectiveness of DC-based vaccines in preclinical in vivo mouse
models, we have developed several models of combination
therapy of DCs with an immunomodulatory drugs, such
as cyclophosphamide or lenalidomide. Cyclophosphamide
is frequently used to enhance or augment the antitumor
eﬀects in cancer immunotherapy [94]. The possible eﬀect
of cyclophosphamide to enhance the antitumor eﬃcacy of
DC vaccine may be due to the increasing proportion of
IFN-γ secreting lymphocytes in combination with the sup-
pressing proportion of CD4+CD25+FoxP3+ Treg cells in
tumor-bearing mice [95]. The result of a clinical trial using
allogeneic DC vaccine combined with low-dose cyclophos-
phamide has revealed that the combination therapy could
induce stronger antitumor response compared with DC vac-
cine alone [96]. Recently, we developed a combination ther-
apy in mouse cancer model which showed that a single
administration of low-dose cyclophosphamide before the
ﬁrst DC vaccination augmented the antitumor eﬀects of DC
vaccinetoeradicatetumorcompletelyandconsequentlypro-
longed the survival of vaccinated mice [89]. Lenalidomide
is a potent anti-myeloma drug which the activity are related
with immunomodulatory properties. Lenalidomide inhibits
Treg expansion and FoxP3 expression on cancer patients
[54]. Our results show that the reduction of suppressor cells
including Treg and MDSC in spleens of lenalidomide vac-
cinated mice in MM model (unpublished data). Therefore,
the combination of DCs with chemotherapy, especially im-
munomodulatory drugs, could regulate and inhibit the
expansion of immunosuppressor cells and signiﬁcantly im-
prove the antitumor eﬀects.
5.7. Regulation the Migratory Pattern of DCs. DCs generated
invitroforvaccinationprotocolsthatcantargetalocallymph
node are highly sought, but diﬃcult to achieve in practice.
Type-1-polarized DCs, with higher levels of IL-12p70 and
potent CTL generation targeting, are, however, limited by
their migratory capacity to primary lymph organs due to the
relatively lower expression of CCR7 compared to sDCs. We
recently reported on the nature of the enhancement of the
migratory phenotype of DCs. The ﬁrst important mediator
in the mobilization of DCs to lymph nodes is CCR7.
However, upregulation of CCR7 alone by DCs is insuﬃcient
to drive DC migration toward CCL19 and CCL21. Up-
regulation of CD38 and downregulation of CD74 regulate
DC migration in vitro and in vivo [97, 98]. By regulating
CD38, CD74, and CCR7 expression on DCs, types I and II
IFNs have synergistic eﬀects in the presence of TLR agonists
on the regulation of DC migration and may provide a novel
approach to improving vaccination eﬃcacy [99].
6. Can Cellular Immunotherapeutic
Methods ImproveMM?
In terms of treatment strategies in MM, the widespread use
of the novel therapies, such as thalidomide, bortezomib and
lenalidomide, has now signiﬁcantly improved the prognosis,
and outcome for patients [100]. The use of these novel ther-
apies in the primary setting together with conventional che-
motherapeutics into early treatment has driven most of the
beneﬁt. However, relapsed and refractory disease remains
an area of challenge, where once prior therapy with im-
munomodulatory agents and proteasome inhibition has
failed, the prognosis remains very poor. An important chal-
lenge that therefore emerges is a risk-adapted approach to
MM therapy [101]. The application of some novel antitumor8 Clinical and Developmental Immunology
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Figure 2: Current suggestion of DC-based vaccines for patients with MM. (1) Vaccination requires the restoration immune system and
the tumor burden is low; (2) new T-cell repertoire induction and elimination of relapse/refractory disease; (3) DC vaccination in alone or
combination; (4) boosting the antitumor immune responses.
agents reveals the new option for high-risk MM. Autologous
and allogeneic stem cell transplantation also still remains the
important therapeutic modality for these patients.
Several studies investigated the point to an inherent
immune system dysregulation that cause the complication
of immunotherapeutic strategies for MM. The dysregulation
in immune cells, the overproduction of immunosuppressive
cytokines, and the proliferation of regulatory T cells and
MDSCs have been associated with many defects in the host
immune system of patients with MM, particularly in the
advanced MM patients [54]. Adoptive transfer of T cells and
NK cells may represent a new immunotherapy for multiple
myeloma. One strategy to improve responses to vaccination
involves combining active vaccination with adoptive T cell
transfer [102]. Adoptive transfer of activated NK cells in
conjunction with IL-2 to myeloma-bearing mice resulted in
prolonged survival compared with treatment with either IL-
2 or activated NK cells alone and the antimyeloma eﬀect was
more potent with a higher dose of NK cells [103].
FortheDC-basedvaccine,severalclinicaltrialsappliedto
the seeing of MM patients after ASCT and these approaches
may reasonable to increase therapeutic eﬀect of DC-based
vaccine in term of minimal residual disease [20, 22–24, 28].
Furthermore, recent study has shown that the immune com-
petence of MM patients can be restored following high dose
chemotherapy and ASCT by a combination of vaccination
and adoptive T-cell therapy [102]. Practically, patients with
refractory and relapsed MM may be not good candidates
to apply the DC-based vaccine, but combination approach
using DC-based vaccine to reduce tumor cells and immune
modulation agents, such as lenalidomide and low-dose
cyclophosphamide, to overcome tumor microenvironment
will be helpful to improve the disease status. The time
point of DC-immunotherapy application was described in
Figure 2.
7. Conclusion
Despitetheirrelativelimitations,thedatafromrecentclinical
studies have suggested that DC-based vaccine may be a
potential therapy in inducing the rate of tumor responses
and prolonging the survival of patients with MM. In an
attempt to increase DC-based potency and improve immune
responses following vaccination, further investigations of
additional tools to identify the alternative tumor antigens
uniquely or speciﬁcally expressed on myeloma cells are
needed, to recover or restore the dysfunction of DCs in
MM patients, to induce T cells with the desirable eﬀector
functions rather than regulatory functions, to migrate into
lymph nodes to stimulate T cells, and to clarify the ability
of tumor-speciﬁc CTLs to recognize and kill tumor cells. In
our expectation, type-1-polarized DCs can be developed to
generate strong functional CTLs. The allogeneic myeloma
cell lines or allogeneic myeloma cells might be an eﬀective
source of universal tumor antigen that could be used to
load to the DC1s for the successful generation of myeloma-
speciﬁc CTLs. Eventually, the combination therapy, in which
a DC vaccine is combined with either alternative therapy
including chemotherapy, radiation therapy, molecular target
therapyorotherimmunotherapy (adoptive therapy,NKcellsClinical and Developmental Immunology 9
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Figure 3: Generation of DC-based vaccines from patients with MM. Isolated monocytes from peripheral blood of patients are cultured
with GM-CSF and IL-4 to produce immature DCs. Immature DCs were matured with α-polarizing cytokines cocktail to generate α-type
1-polarized DCs and were loaded with apoptotic bodies from myeloma cells or myeloma cell line which were induced in the presence of
bortezomib and JSI-124. Tumor antigens-loaded DCs were then injected into patients in combination with either cyclophosphamide or
lenalidomide to induce strong immune responses against the tumor.
therapy), or with adjuvant, will provide vigorous and main-
tained immune responses with the beneﬁt clinical eﬃcacy.
The most promising DC-based vaccine in patients with MM
was described in Figure 3.
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